Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP137 with Azacitidine and Venetoclax in Refractory AML
NCT06150040Phase 2Terminated
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of np137 in acute myeloid leukemia (AML), sponsored by Centre Léon Bérard. Primary endpoints: Incidence of Dose Limiting Toxicities at 4 weeks and Objective Response Rate at 16 weeks. Started Sep 2024; status: terminated.
02
Drugs
np137
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06150040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150040.